|16. Switch to an IL-17i biologic monotherapy over MTX and an IL-17i biologic combination therapy (PICO 21)|Very low|
|Conditional recommendation based on very-low-quality evidence; may consider MTX and an IL-17i biologic combination therapy if the patient has severe skin manifestations, has had a partial response to current MTX therapy, or has concomitant uveitis (since uveitis may respond to MTX therapy).|Conditional recommendation based on very-low-quality evidence; may consider MTX and an IL-17i biologic combination therapy if the patient has severe skin manifestations, has had a partial response to current MTX therapy, or has concomitant uveitis (since uveitis may respond to MTX therapy).|
|17. Switch to an IL-12/23i biologic monotherapy over MTX and an IL-12/23i biologic combination therapy (PICO 20)|Very low|